Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome

被引:522
作者
Ehrmann, DA
Liljenquist, DR
Kasza, K
Azziz, R
Legro, RS
Ghazzi, MN
机构
[1] Univ Chicago, Endocrinol Sect, Pritzker Sch Med, Dept Med, Chicago, IL 60637 USA
[2] Univ Chicago, Dept Hlth Studies, Pritzker Sch Med, Chicago, IL 60637 USA
[3] Univ Alabama Birmingham, Dept Obstet & Gynecol, Birmingham, AL 35294 USA
[4] Penn State Univ, Dept Obstet & Gynecol, Hershey, PA 17033 USA
[5] Pfizer Pharmaceut Inc, Ann Arbor, MI 48105 USA
关键词
D O I
10.1210/jc.2005-1329
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Polycystic ovary syndrome (PCOS) and the metabolic syndrome have many features in common and may share the same pathogenesis. Objective: This study was performed to determine the prevalence and predictors of the metabolic syndrome in PCOS. Design: The clinical, hormonal, and oral glucose tolerance test results were analyzed in 394 PCOS women who were screened for participation in a multicenter trial to evaluate the effects of troglitazone on ovulation and hirsutism. Setting: A multicenter clinical trial is presented. Patients or Other Participants: The subjects were women with PCOS who had or lacked the metabolic syndrome. Main Outcome Measures: Waist circumference, fasting glucose, high-density lipoprotein cholesterol and triglyceride concentrations, and blood pressure were the main outcome measures. Results: Twenty-six (6.6%) subjects had diabetes; among the 368 nondiabetics, the prevalence for individual components comprising the metabolic syndrome were: waist circumference greater than 88 cm in 80%, high-density lipoprotein cholesterol less than 50 mg/dl in 66%, triglycerides greater than or equal to 150 mg/dl in 32%, blood pressure greater than or equal to 130/85 mm Hg in 21%, and fasting glucose concentrations greater than or equal to 110 mg/dl in 5%. Three or more of these individual criteria were present in 123 (33.4%) subjects overall. The prevalence of the metabolic syndrome did not differ significantly between racial/ethnic groups. The prevalence of the metabolic syndrome from lowest to highest quartile of free testosterone concentration was 19.8, 31.3, 46.9, and 35.0%, respectively [P=0.056 adjusted for body mass index (BMI)]. None of the 52 women with a BMI less than 27.0 kg/m(2) had the metabolic syndrome; those in the top BMI quartile were 13.7 times more likely (95% confidence interval, 5.7-33.0) to have the metabolic syndrome compared with those in the lowest quartile. Thirty-eight percent of those with the metabolic syndrome had impaired glucose tolerance compared with 19% without the metabolic syndrome (P<0.001). Conclusions: The metabolic syndrome and its individual components are common in PCOS, particularly among women with the highest insulin levels and BMI. Hyperinsulinemia is a likely common pathogenetic factor for both PCOS and the metabolic syndrome.
引用
收藏
页码:48 / 53
页数:6
相关论文
共 26 条
  • [1] Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome
    Apridonidze, T
    Essah, PA
    Iuorno, MJ
    Nestler, JE
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (04) : 1929 - 1935
  • [2] The prevalence and features of the polycystic ovary syndrome in an unselected population
    Azziz, R
    Woods, KS
    Reyna, R
    Key, TJ
    Knochenhauer, ES
    Yildiz, BO
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (06) : 2745 - 2749
  • [3] Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: A multicenter, double blind, placebo-controlled trial
    Azziz, R
    Ehrmann, D
    Legro, RS
    Whitcomb, RW
    Hanley, R
    Fereshetian, AG
    O'Keefe, M
    Ghazzi, MN
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (04) : 1626 - 1632
  • [4] Screening women with polycystic ovary syndrome for metabolic syndrome
    Dokras, A
    Bochner, M
    Hollinrake, E
    Markham, S
    VanVoorhis, B
    Jagasia, DH
    [J]. OBSTETRICS AND GYNECOLOGY, 2005, 106 (01) : 131 - 137
  • [5] Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis
    Dunaif, A
    [J]. ENDOCRINE REVIEWS, 1997, 18 (06) : 774 - 800
  • [6] Medical progress: Polycystic ovary syndrome
    Ehrmann, DA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (12) : 1223 - 1236
  • [7] Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome
    Ehrmann, DA
    Barnes, RB
    Rosenfield, RL
    Cavaghan, MK
    Imperial, J
    [J]. DIABETES CARE, 1999, 22 (01) : 141 - 146
  • [8] Body composition, fat distribution and metabolic characteristics in lean and obese women with polycystic ovary syndrome
    Faloia, E
    Canibus, P
    Gatti, C
    Frezza, F
    Santangelo, M
    Garrapa, GGM
    Boscaro, M
    [J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2004, 27 (05) : 424 - 429
  • [9] The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study
    Ford, ES
    [J]. ATHEROSCLEROSIS, 2004, 173 (02) : 309 - 314
  • [10] Prevalence of the metabolic syndrome among US adults - Findings from the Third National Health and Nutrition Examination Survey
    Ford, ES
    Giles, WH
    Dietz, WH
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (03): : 356 - 359